Loading...
•
Jun 30, 2021
Checkpoint Therapeutics Q2 2021 Earnings Report
Announced second quarter 2021 financial results and completion of enrollment in pivotal cohort for cosibelimab.
Key Takeaways
Checkpoint Therapeutics announced the completion of enrollment in the pivotal cohort of patients with metastatic cutaneous squamous cell carcinoma in the registration-enabling clinical trial for cosibelimab, with top-line data expected in the fourth quarter of this year.
Completed enrollment in the pivotal cohort of patients with metastatic cutaneous squamous cell carcinoma for cosibelimab.
Expect to report top-line data for cosibelimab in the fourth quarter of this year.
Intend to submit a Biologics License Application for cosibelimab in 2022, followed by a Marketing Authorization Application submission in Europe.
Had productive interactions with the FDA regarding the development program for olafertinib.
Forward Guidance
Checkpoint Therapeutics is focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...